2024-04-24 10:33:24 ET
Summary
- Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose.
- The company has seen impressive results from a phase 3 study of PH94B in patients with social anxiety disorder, leading to a significant increase in stock value.
- Vistagen Therapeutics is also exploring the potential of PH10, or itruvone, in treating major depressive disorder, with plans for a phase 2b study.
...
Read the full article on Seeking Alpha
For further details see:
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression